MedTrace Logo

Quarterback 2b - Sequential Therapy With Reduced Dose Chemoradiotherapy for HPV Oropharynx Cancer

NCT02945631 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2026-04-02

No results posted yet for this study

Summary

The purpose of this study is to establish the efficacy and toxicity of low dose chemoradiotherapy after induction chemotherapy in patients with locally advanced HPV+ oropharynx cancer and establish prognostic factors that would apply to help select patients for this treatment in the future.

Conditions

  • Locally Advanced HPV Positive Oropharynx Cancer

Interventions

RADIATION

PTV56

total dose of 56 Gy in 2.0 Gy/fraction x 28 fractions.

RADIATION

PTV50.4

total dose of 50.4 Gy in 1.8 Gy /fraction x 28 fractions.

Sponsors & Collaborators

Principal Investigators

  • Krysztof Misiukiewicz, MD · Icahn School of Medicine at Mount Sinai

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-25
Primary Completion
2027-12-31
Completion
2027-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02945631 on ClinicalTrials.gov